Frilling A, Malago M, Martin H, Broelsch C E
Department of General Surgery, University Hospital Hamburg, Germany.
Surgery. 1998 Dec;124(6):1000-4. doi: 10.1067/msy.1998.93919.
The presence of lymph node metastases significantly influences the modality of treatment in patients with liver metastases of neuroendocrine tumors (NET). Somatostatin receptor scintigraphy (Octreo-Scan, Mallinckrodt-Diagnostica, Petten, the Netherlands) is a method for localization and staging NET. The aim of our prospective study was to evaluate the effectiveness of somatostatin receptor scintigraphy in the identification of extrahepatic tumor spread.
Thirty-five patients with liver metastases of NET were studied over a 5-year period. The presence of NET was confirmed histologically in all cases. To detect extrahepatic metastases or local tumor recurrence, conventional imaging techniques and somatostatin receptor scintigraphy were carried out.
In correlation with the findings of conventional imaging methods, somatostatin receptor scintigraphy confirmed liver metastases in all patients. Additionally, 19 of 35 patients (54.2%) had extrahepatic tumor lesions not detected by other imaging techniques. Of those, 15 had extensive abdominal or thoracic lymph node metastases, 3 patients had bone metastases, and in 1 patient with bronchial carcinoid local tumor recurrence was detected. All 19 patients were excluded from further evaluation for liver resection or transplantation and subjected to conservative treatment. The somatostatin receptor scintigraphy sensitivity, confirmed at the time of operation, was 91.6%. In 1 patient, in whom cluster transplantation was performed, somatostatin receptor scintigraphy failed to disclose disseminated carcinosis of the pleural cavity, detected at autopsy (false-negative rate 8.3%).
In our experience, somatostatin receptor scintigraphy provides a highly sensitive diagnostic method to localize metastases of NET. We recommend somatostatin receptor scintigraphy before liver surgery in every patient with hepatic metastases of NET to identify candidates suitable for resection.
淋巴结转移的存在显著影响神经内分泌肿瘤(NET)肝转移患者的治疗方式。生长抑素受体闪烁扫描术(奥曲肽扫描,Mallinckrodt - Diagnostica公司,荷兰佩滕)是一种用于NET定位和分期的方法。我们前瞻性研究的目的是评估生长抑素受体闪烁扫描术在识别肝外肿瘤扩散方面的有效性。
在5年期间对35例NET肝转移患者进行了研究。所有病例均经组织学证实存在NET。为了检测肝外转移或局部肿瘤复发,进行了传统成像技术和生长抑素受体闪烁扫描术。
与传统成像方法的结果相关,生长抑素受体闪烁扫描术证实所有患者均有肝转移。此外,35例患者中有19例(54.2%)存在其他成像技术未检测到的肝外肿瘤病变。其中,15例有广泛的腹部或胸部淋巴结转移,3例有骨转移,1例支气管类癌患者检测到局部肿瘤复发。所有19例患者均被排除进一步评估肝切除或移植,并接受了保守治疗。手术时证实生长抑素受体闪烁扫描术的敏感性为91.6%。1例接受簇状移植的患者,生长抑素受体闪烁扫描术未能发现尸检时检测到的胸膜腔播散性癌(假阴性率8.3%)。
根据我们的经验,生长抑素受体闪烁扫描术为NET转移灶定位提供了一种高度敏感的诊断方法。我们建议对每例NET肝转移患者在肝脏手术前进行生长抑素受体闪烁扫描术,以识别适合切除的候选者。